A live-attenuated vaccine is a vaccine containing living microorganisms whose ability to cause disease has been substantially reduced while their capacity to replicate sufficiently to stimulate immunity is retained. Most contain weakened viruses, although some contain bacteria. By producing a limited infection, these vaccines expose the immune system to microbial components in a way that resembles natural infection without ordinarily causing the associated disease. Their safety and effectiveness depend on the vaccine strain, the recipient’s immune status, and the conditions under which the product is manufactured, stored, and administered.
Biological principles
Attenuation is a reduction in a microorganism’s disease-causing capacity, or virulence. An attenuated organism may replicate less efficiently in human tissues, have a restricted ability to spread within the body, or grow effectively only under particular conditions. Attenuation does not necessarily eliminate every possibility of disease.
After administration, limited replication provides a continuing supply of microbial antigens—structures recognized by the immune system. This activates both early innate defenses and adaptive immune responses. Protection can involve antibodies, T cells, and long-lived immune memory. Vaccines administered orally or intranasally can also stimulate immunity at mucosal surfaces, although the strength and importance of this response vary by product.
Live-attenuated vaccines often produce strong, durable protection with relatively few doses. This is not universal: some require multiple doses to establish reliable immunity or maintain protection. Additional doses may address failure to respond to an earlier dose rather than simply compensate for declining immunity.
Unlike a live-attenuated vaccine, an inactivated vaccine contains organisms rendered incapable of replication. A subunit vaccine contains selected microbial components rather than a complete, replicating organism.
Methods of attenuation
Several approaches can produce vaccine strains:
- Serial passage: Repeated growth in cultured cells, eggs, or a different host can select organisms adapted to those conditions but less capable of causing disease in humans.
- Temperature adaptation: Selection can produce strains that replicate efficiently at cooler temperatures but poorly at temperatures found deeper in the body. This principle is used in live-attenuated influenza vaccines.
- Targeted genetic modification: Specific changes to a microorganism’s genes can reduce virulence or restrict replication.
- Reassortment or chimeric construction: Some viral vaccines combine genetic material from different strains or related viruses to obtain suitable attenuation and immune recognition.
These approaches are not mutually exclusive. A licensed strain must be evaluated for characteristics such as genetic stability, residual virulence, immune response, and manufacturing consistency. The number of genetic changes alone does not establish safety.
Major examples
Live-attenuated vaccines are used against several viral and bacterial diseases. Availability, licensed ages, formulations, and use in national immunization programs differ between countries.
| Vaccine | Principal characteristics |
|---|---|
| Measles, mumps, and rubella vaccines | Commonly administered together as MMR; contain attenuated viruses, including the virus used to prevent [[measles |
| Varicella vaccine | Contains attenuated varicella-zoster virus and prevents [[chickenpox |
| Yellow fever vaccine | Uses derivatives of the attenuated 17D strain. |
| Rotavirus vaccines | Oral vaccines containing live attenuated or reassortant viruses. |
| Oral poliovirus vaccine | Contains attenuated polioviruses; formulations differ in the types of virus included. |
| Live-attenuated influenza vaccine | An intranasal vaccine containing temperature-sensitive, cold-adapted viruses. |
| Bacille Calmette–Guérin vaccine | A live bacterial vaccine derived from Mycobacterium bovis, used against [[tuberculosis |
| Ty21a typhoid vaccine | An oral vaccine containing attenuated Salmonella Typhi. |
Some cholera and dengue vaccines also use live-attenuated organisms. Vaccines against the same disease are not necessarily interchangeable: their biological properties, evidence base, and licensed indications can differ substantially.
Historical development
Experimental attenuation became a foundation of vaccine development in the late nineteenth century, notably through Louis Pasteur’s work on chicken cholera and anthrax.
Bacille Calmette–Guérin, generally called BCG, was developed through repeated culture of M. bovis and first administered to a human in 1921. The yellow fever 17D strain was developed in the 1930s. Advances in cell culture subsequently enabled the development and large-scale production of several live viral vaccines, including oral poliovirus and measles vaccines.
Earlier smallpox vaccination, associated with Edward Jenner, used related orthopoxviruses rather than simply a weakened version of the smallpox virus. It is therefore historically related to live vaccination but not an exact example of attenuation of the target pathogen.
Safety and limitations
Replication in susceptible recipients
Because vaccine organisms remain capable of replication, they can occasionally cause serious disease, particularly in people with certain forms of immunodeficiency or substantial immunosuppression. The degree of risk differs between vaccines and immune conditions; the category “live vaccine” alone does not determine eligibility.
Many live-attenuated vaccines are contraindicated during pregnancy because of potential fetal risk. The evidence and regulatory wording are product-specific. A precautionary contraindication does not itself establish that fetal injury has been observed after inadvertent exposure.
Shedding, transmission, and genetic change
Shedding is the release of a vaccine organism from a recipient. It does not necessarily imply transmission to another person, and transmission does not necessarily imply disease. These properties vary substantially between vaccine strains.
Oral poliovirus vaccine illustrates an important, uncommon limitation. Its strains can rarely cause vaccine-associated paralytic disease. When vaccine-derived viruses circulate for prolonged periods in insufficiently immunized populations, they can accumulate mutations and regain properties associated with paralysis and sustained transmission. This differs from an ordinary, expected vaccine reaction.
Reversion to increased virulence is not a uniform feature of live-attenuated vaccines. For many established vaccine strains, it is not a recognized practical problem.
Interference and variable response
Maternal antibodies can reduce the response to some live vaccines administered early in infancy. Certain antibody-containing blood products can similarly interfere with selected live viral vaccines. Other factors, including intestinal infections and nutritional conditions, may affect the performance of some oral vaccines.
No vaccine guarantees complete protection in every recipient. Protection against severe disease may also differ from protection against infection or onward transmission.
Storage, quality control, and public-health use
Many live-attenuated vaccines are sensitive to heat or light and require a controlled cold chain. Some are supplied as freeze-dried preparations that must be reconstituted. Storage requirements and allowable time after reconstitution are specific to each product; live vaccines do not all require identical handling.
Manufacturing controls assess identity, purity, potency, and freedom from unwanted microbial contamination. Potency testing must account for the quantity of viable vaccine organisms, because loss of viability can reduce effectiveness.
In public-health programs, live-attenuated vaccines can reduce disease directly and, when they reduce infection or transmission, contribute to herd immunity. Their use requires product-specific assessment of disease burden, immune responses, rare adverse events, delivery requirements, and available alternatives. Pharmacovigilance and public-health surveillance continue after introduction to detect uncommon safety problems and monitor effects at population level.